Literature DB >> 2464637

Activation of cloned human natural killer cells via Fc gamma RIII.

T Werfel1, P Uciechowski, P A Tetteroo, R Kurrle, H Deicher, R E Schmidt.   

Abstract

The Fc gamma RIII (CD16) Ag on human NK cells involved in antibody-dependent cellular cytotoxicity has been demonstrated to be an important activation structure. The present studies were carried out to further characterize the functional role of the CD16 Ag and the mechanisms whereby cytotoxicity is activated by using human NK clones. In phenotypic studies Fc gamma RIII was found to be expressed heterogeneously on various human cloned NK cells. Expression on CD3- and CD3+ clones varied with the donor and mAb used for detection. Functional data demonstrated that cytotoxicity against NK-resistant target cells can be induced in CD3-CD16+ NK clones and CD3+CD16+ clones with NK activity when various CD16 mAb were used. CD16 antibodies but not reactive isotype control antibodies induced cytotoxicity. In contrast to complete CD16 antibodies F(ab')2 fragments were not able to activate the cytotoxic mechanism. Both an antibody against FcR on the target cell (Fc gamma RII) and a CD11a antibody blocked induction of cytotoxicity. These results suggest that three steps are critical for activation of CD16+ cells via Fc gamma RIII: 1) specific binding of CD16 antibodies to Fc gamma RIII on effector cells irrespective of the epitope recognized; 2) cross-linking of effector cell CD16 Ag through binding of the Fc site of CD16 antibodies via corresponding FcR on the target cell membrane; and 3) interaction of CD11a/18 molecules with the target cell membrane.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464637

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Defect of a complement receptor 3 epitope in a patient with systemic lupus erythematosus.

Authors:  T Witte; F L Dumoulin; J E Gessner; J Schubert; O Götze; C Neumann; R F Todd; H Deicher; R E Schmidt
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

2.  Heterogeneity of human natural killer cells in the spleen.

Authors:  T Witte; K Wordelmann; R E Schmidt
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

3.  Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.

Authors:  P Anderson; M Caligiuri; C O'Brien; T Manley; J Ritz; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

4.  Soluble Fc gamma receptor III in human plasma originates from release by neutrophils.

Authors:  T W Huizinga; M de Haas; M Kleijer; J H Nuijens; D Roos; A E von dem Borne
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

5.  CD45 molecule cross-linking inhibits natural killer cell-mediated lysis independently of lytic triggering.

Authors:  G C Starling; D N Hart
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

Review 6.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Characterization of B-cell lines from SLE patients and their relatives.

Authors:  T Witte; K Hartung; F M Bode; R E Schmidt; H Deicher
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

8.  Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity.

Authors:  Bettina Drescher; Torsten Witte; Reinhold E Schmidt
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

9.  Nasal lavage natural killer cell function is suppressed in smokers after live attenuated influenza virus.

Authors:  Katherine M Horvath; Margaret Herbst; Haibo Zhou; Hongtao Zhang; Terry L Noah; Ilona Jaspers
Journal:  Respir Res       Date:  2011-08-04

Review 10.  Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine.

Authors:  Carolyn M Boudreau; Galit Alter
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.